Top 5 Sliver Stocks To Own For 2014

After a difficult multiyear period, original DVR innovator TiVo (NASDAQ: TIVO  ) once again has profitability within its grasp. The company recently posted Street-beating earnings for the first quarter, and forecast the coming year to investors' and analysts' delight. Still, TiVo operates in a hyper-competitive, technology-driven business. This makes it a difficult investment prospect that should only appeal to investors if it is determined to have a wide margin of safety. After a one-year gain of more than 30%, can TiVo still offer investors upside potential, or has the company's recovery already been priced into the stock?

Earnings recap
The name of the game for the recently ended quarter was subscriber growth. Even though the company still posted a net loss, subscribers drifted up 277,000 in the quarter -- the most substantial quarterly gain in seven years. The news helped bring the stock to its 52-week high early this week.

As for the financials, things certainly improved over the year-ago quarter. Perhaps the most important fact for investors to take in is that the company did achieve EBITDA profitability, which even management seemed surprised at given a hefty litigation expense for the quarter. The company earned $800,000 in EBITDA, and is set to remain in the black for the remainder of the year (again, in terms of EBITDA). Without the $10.9 million litigation expense with Motorola, TiVo would have brought in $12 million in EBITDA.

Top 5 Sliver Companies To Invest In 2015: Eaton Vance Limited Duration Income Fund (EVV)

Eaton Vance Limited Duration Income Fund is a closed-ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in the fixed income markets of the United States. It seeks to invest in the securities of companies operating across the diversified sectors. The fund invests in senior, secured floating-rate loans, mortgage-backed securities, and corporate bonds that are rated below investment grade quality, known as junk bonds with an average duration of 3.47 years and average quality BBB/BBB-. It benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index, the Merrill Lynch U.S. High Yield Index, and the Barclays Capital U.S. Intermediate Government Bond Index. Eaton Vance Limited Duration Income Fund was formed on May 30, 2003 and is domiciled in the United States.

Advisors' Opinion:

• [By Adam Aloisi]

  The following chart takes a comparative look at some widely held ETFs/CEFs holding different types of bonds. The objective is to visualize not only how much these products cost, but also to break down the percent of total yield depleted by management fees. I define total yield as current annualized yield plus net fees - in other words the yield of the fund if there were no management fees attached. The funds we will examine are aforementioned BND, iShares 20+ Treasury Bond (TLT), iShares High-Yield Corporate (HYG), Nuveen Municipal Value (NUV), Eaton Vance Limited Duration (EVV) and Alliance Bernstein Global High-Yield (AWF).

Top 5 Sliver Stocks To Own For 2014: Waste Connections Inc. (WCN)

Waste Connections, Inc., an integrated solid waste services company, provides solid waste collection, transfer, disposal, and recycling services. The company also offers intermodal services, including repositioning, storage, maintenance, and repair of cargo containers for international shipping companies for the rail haul movement of cargo and solid waste containers in the Pacific Northwest. In addition, it provides container and chassis sales and leasing services to its customers. Further, the company offers residential, commercial, and industrial solid waste collection services; and provides recycling services for various recyclable materials, including cardboard, office paper, plastic containers, glass bottles, and ferrous and aluminum metals. Its transfer stations receive, compact, and load solid waste to be transported to landfills via truck, rail, or barge. As of December 31, 2010, the company owned or operated a network of 135 solid waste collection operations, 54 t ransfer stations, 39 recycling operations, 44 active landfills, and 7 intermodal facilities, as well as one exploration and production waste treatment and disposal facility. It serves approximately two million residential, commercial, and industrial customers from a network of operations in 27 states in the United States. The company was founded in 1997 and is based in Folsom, California.

Advisors' Opinion:

• [By Sean Williams]

  Other players in the field, such as Waste Connections (NYSE: WCN  ) , have viewed traditional refuse collection as too crowded and have looked toward unique ways of boosting their bottom line. Waste Connection last year purchased R360 Environmental Solutions for $1.3 billion to get a foothold in the oil and natural gas industry. R360 generates revenue by cleaning contaminated fields, recovering oil from storage tanks, and washing drilling facilities.

• [By Marc Bastow]

  Integrated municipal solid waste services company Waste Connections (WCN) raised its quarterly dividend 15% to 11.5 cents per share, payable on Nov. 19 to shareholders of record as of Nov. 5.
  WCN Dividend Yield:�1.04%

• [By Rich Smith]

  Treasure in trash
  Markets are up modestly in early trading Monday, and one company leading the way upwards is trash collector Waste Connections (NYSE: WCN  ) . Up nearly 39% over the past year, and up nearly twice as much as the S&P 500, Waste Connections got a further boost today when analysts at Stifel Nicolaus raised their price target on the stock to $47 a share.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Waste Connections (NYSE: WCN  ) , whose recent revenue and earnings are plotted below.

Top 5 Sliver Stocks To Own For 2014: Aegerion Pharmaceuticals Inc.(AEGR)

Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood. Its lead product, lomitapide has completed pivotal Phase III clinical trial to treat patients with a rare inherited lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The company also plans to develop lomitapide for the treatment of adult patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Brian Orelli]

  According to an abstract posted at Forbes, Amgen's PCSK9 inhibitor was able to help some patients with a rare genetic disease that causes extremely high levels of cholesterol. For some patients, the drug, dubbed AMG 145, seems to work as well as Aegerion's (NASDAQ: AEGR  ) Juxtapid�or Kynamro from Isis Pharmaceuticals (NASDAQ: ISIS  ) and Sanofi, without the side effects. In addition to taking some sales from Juxtapid and Kynamro, AMG145 looks poised to treat patients with less severe cholesterol problems given the clean side effect profile.

• [By MONEYMORNING.COM]

  Aegerion PharmaceuticalsInc. (Nasdaq: AEGR) developed a drug, Juxtapid, for a rare genetic condition called homozygous familial hypercholesterolemia, or HoFH, that can raise a person's cholesterol levels to more than 1,000 mg/dL. A healthful level is considered to be less than 200 mg/dL. The disease largely affects kids, who can die of heart attack by age 2. Most are dead by age 11. When Juxtapid hit the market, it was the only therapy available. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS) would soon join in the competition with its less expensive injectable drug, Kynamro, but Juxtapid had fewer side effects and could be administered orally.

• [By Brian Orelli]

  We've got a blockbuster
  Aegerion Pharmaceuticals' (NASDAQ: AEGR  ) big spike in mid-May came after management said at a Bank of America Merrill Lynch health-care conference that its cholesterol-lowering drug Juxtapid�could have a $1 billion market for the genetic disease it treats. Analysts quickly regurgitated the biotech company's assertions, increasing their price targets accordingly.

• [By Ernie Tremblay, Biosciences Specialist, Money Morning | January 17, 2014 · ]

  Back in August 2012, I noticed that a tiny biotech called Aegerion Pharmaceuticals (Nasdaq: AEGR) was about to present lomitapide, the one and only drug in its pipeline, to an FDA AdCom (Advisory Committee). AdComs are catalysts, key points in the drug development regulatory process that can make a company's stock soar - or nosedive.

Top 5 Sliver Stocks To Own For 2014: Concord Medical Services Holdings Limited (CCM)

Concord Medical Services Holdings Limited, together with its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People�s Republic of China. The company�s services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, proton beam therapy, diagnostic imaging, and other treatment and diagnostic modalities. It offers clinical support services; develops treatment protocols for doctors; and organizes joint diagnosis between doctors in its network and clinical research. The company also operates a specialty cancer hospital, as well as leases medical and diagnostic equipment. As of March 31, 2011, it operated a network of 121 centers with 68 hospital partners that cover 46 cities and 24 provinces, and administrative regions in China. The company was founded in 1996 and is headquartered in Beijing, the People�s Republic of China.

Advisors' Opinion:

• [By John Udovich]

  China is set to ease the one child policy, something that could benefit Chinese stocks in general but be especially beneficial to insurance stocks like China Life Insurance Company Ltd (NYSE: LFC) and CNinsure Inc (NASDAQ: CISG) plus health care stocks like Mindray Medical International Ltd�(NYSE: MR) and Concord Medical Services Hldg Ltd (NYSE: CCM). First, let�� be clear that China is NOT abolishing the one child policy as the changes will merely�allow married couples to have two children if one spouse is an only child plus it will be up to China�� 34 province-level administrations to revise�their laws and put the new policy into effect. Moreover, China�� family-planning bureaucracy employs more than 500,000 full-time workers and six million part-time workers all the way down to the village level to�collect billions of dollars in fines and these bureaucrats have fought for years against policy changes���meaning they could throw up roadblocks if not placated. With that said, the insurance and health care sectors are two sectors with publicly Chinese stocks that look set to�take advantage of the coming changes.